This session will take place on 10th September at 13:00 CEST.
Chairperson(s): S. Vujosevic ITALY
Chairperson
13:00 Welcome and introduction
R. Gale UK
13:01 Long-term efficacy outcomes with Brolucizumab vs Aflibercept treatment in patients with early residual fluid presence in nAMD: post hoc analysis of pooled data from HAWK & HARRIER studies
J. Ehlers USA
13:05 The safety-specific, next-generation optical coherence tomography analysis from HAWK: preliminary qualitative OCT findings associated with intraocular inflammation
All Faculty
13:09 Discussion
S. Wolf SWITZERLAND
13:15 Association between visual acuity and intraretinal or subretinal fluid in patients with neovascular age-related macular degeneration treated with intravitreal aflibercept treat-and-extend: A post hoc analysis of the ARIES study
M. Gillies AUSTRALIA
13:19 Shorter treatment intervals are associated with higher treatment compliance than longer treatment intervals in a treat-and-extend regimen for nAMD
All Faculty
13:23 Discussion
R. MacLaren UK
13:29 Preliminary results from a first-in-human Phase I/II gene therapy study (FOCUS) of GT005, an investigational AAV2 vector encoding complement factor I, in patients with geographic atrophy
C. Jamison UK
13:33 Idiopathic serous epithelial detachments (SPEDs) and choroidal thickness in UK Biobank (UKBB)
All Faculty
13:37 Discussion
13:45 End of Session
The programme schedule may be subject to change. Please refer to the interactive programme for the most up to date details.
